Evidence map›Paper›PMID 39560957›Full record

Trial reportLeukemia & lymphoma2025

Cost-effectiveness of Enasidenib versus conventional care for older patients with

Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica M Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, George Goshua and 2 more

Abstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abdulrahman AlhajahjehThe University of Jordan, School of Medicine, Amman, Jordan.
Kishan K PatelDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rory M ShallisSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-8542-2944
Nikolai A PodoltsevSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Tariq KewanSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Jessica M StempelSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Lourdes MendezSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Scott F HuntingtonSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Maximilian StahlDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
George GoshuaSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-1624-4427
Jan Philipp BewersdorfSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-3352-0902
Amer M ZeidanSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)T32CA233414 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 2019 to 2026
$3.2M
Targeted, adaptive and time-variant strategies for bleed prevention across the lifespan for persons with hemophilia AK01HL175220 · NHLBI · YALE UNIVERSITY · PI George Goshua · 2024 to 2026
$520k
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA233414NHLBI NIH HHS K01 HL175220
6 · The paper itself

Abstract

In the randomized phase III IDHENTIFY trial, the IDH2 inhibitor enasidenib (ENA) showed improvement in event-free but not overall survival compared with conventional care regimens (CCR) among patients with relapsed/refractory (R/R),

Indexed as

AminopyridinesIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMutationNeoplasm Recurrence, LocalTriazinesAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCost-Benefit AnalysisDrug Resistance, NeoplasmFemaleHumansMaleQuality-Adjusted Life YearsTreatment OutcomeAminopyridinesenasidenibIDH2 protein, humanIsocitrate DehydrogenaseTriazinesAcute myeloid leukemiacost-effectiveness analysisenasidenibIDH2 mutation

Identifiers

PMID39560957
PMCPMC12138910

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.